Amgen Research (munich) Gmbh

Amgen Inc.

Boehringer Ingelheim International Gmbh

Amgen Research Gmbh

Ralf Lutterbuese

Peter Kufer

Tobias Raum

Patrick Hoffmann

Doris Rau

Roman Kischel

Susanne Hipp

Barbara Hebeis

Eric Borges

Paul Adam

Elisabeth Nahrwold

Shouhua Xiao

Dineli Wickramasinghe

Birgit Kohleisen

Zheng Pan

Chadwick Terence King

Holger Wesche

Bryan D Lemon

Claudia Blümel

Benno Rattel

Christoph Dahlhoff

Matthias Klinger

Susanne Mangold

Jochen Pendzialek

Johannes Brozy

Matthias Friedrich

Evelyne Schaller

Markus Münz

Brian Mingtung Chan

Petra Fluhr

Markus Muenz

M Shawn Jeffries

Steven Zeman

Ines Herrmann

Olivier Nolan-Stevaux

Susanne Hausmann

Carola Steiger

Claudia Bluemel

Marc Panzer

Wibke Deisting

Majk Kvesic

Ulla Lenkkeri-Schuetz

Markus Munz

Patrick Baeuerle

The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

Binding molecules for BCMA and CD3

The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster3 of BCMA, and the second binding domain is capable of binding to the Tcell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of the binding molecule and a kit comprising the binding molecule.

The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

Cross-species-specific PSMAxCD3 bispecific single chain antibody

Growing community of inventors

Munich, Germany

Ralf Lutterbuese